Dynavax Technologies reported $179.42M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Abbvie ABBV:US $ 6098M 3648M
Adma Biologics ADMA:US $ 69.5M 18.42M
Agenus AGEN:US $ 247.71M 44.22M
Amgen AMGN:US $ 6528M 1461M
AstraZeneca AZN:LN 5762M 567M
Astrazeneca AZN:US $ 5762M 567M
Biogen BIIB:US $ 1749.3M 512.1M
Biomarin Pharmaceutical BMRN:US $ 605.44M 18.16M
Bristol Myers Squibb BMY:US $ 12369M 1610M
Chimerix CMRX:US $ 31.96M 16.56M
Dynavax Technologies DVAX:US $ 179.42M 256.77M
Gilead Sciences GILD:US $ 4296M 1042M
Glaxosmithkline GSK:US $ 10967M 6693M
Idera Pharmaceuticals IDRA:US $ 27.99M 4.55M
Merk MRK:US $ 8556M 460M
Minerva Neurosciences NERV:US $ 54.95M 5.81M
Nektar Therapeutics NKTR:US $ 67.99M 42.78M
Neurocrine Biosciences NBIX:US $ 270.2M 70.6M
Novartis NOVN:VX SF 13852M 1445M
Pfizer PFE:US $ 2470M 526M
Regeneron Pharmaceuticals REGN:US $ 3345.7M 460.1M
Sarepta Therapeutics SRPT:US $ 1233.88M 881.99M
Tg Therapeutics TGTX:US $ 185.68M 113.21M
Vertex Pharmaceuticals VRTX:US $ 7600.1M 805.1M